These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 28934595)

  • 1. Chronic Obstructive Pulmonary Disease Alters Immune Cell Composition and Immune Checkpoint Inhibitor Efficacy in Non-Small Cell Lung Cancer.
    Mark NM; Kargl J; Busch SE; Yang GHY; Metz HE; Zhang H; Hubbard JJ; Pipavath SNJ; Madtes DK; Houghton AM
    Am J Respir Crit Care Med; 2018 Feb; 197(3):325-336. PubMed ID: 28934595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impaired Tumor-Infiltrating T Cells in Patients with Chronic Obstructive Pulmonary Disease Impact Lung Cancer Response to PD-1 Blockade.
    Biton J; Ouakrim H; Dechartres A; Alifano M; Mansuet-Lupo A; Si H; Halpin R; Creasy T; Bantsimba-Malanda C; Arrondeau J; Goldwasser F; Boudou-Rouquette P; Fournel L; Roche N; Burgel PR; Goc J; Devi-Marulkar P; Germain C; Dieu-Nosjean MC; Cremer I; Herbst R; Damotte D
    Am J Respir Crit Care Med; 2018 Oct; 198(7):928-940. PubMed ID: 29518341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distribution of CD4(+) and CD8(+) T cells in tumor islets and stroma from patients with non-small cell lung cancer in association with COPD and smoking.
    Jackutė J; Žemaitis M; Pranys D; Šitkauskienė B; Miliauskas S; Bajoriūnas V; Sakalauskas R
    Medicina (Kaunas); 2015 Nov; 51(5):263-71. PubMed ID: 26674143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dysregulation of Antiviral Function of CD8(+) T Cells in the Chronic Obstructive Pulmonary Disease Lung. Role of the PD-1-PD-L1 Axis.
    McKendry RT; Spalluto CM; Burke H; Nicholas B; Cellura D; Al-Shamkhani A; Staples KJ; Wilkinson TM
    Am J Respir Crit Care Med; 2016 Mar; 193(6):642-51. PubMed ID: 26517304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lung tissue and tumour-infiltrating T lymphocytes in patients with non-small cell lung carcinoma and chronic obstructive pulmonary disease (COPD): moderate/severe versus mild stage of COPD.
    Marc MM; Korosec P; Kern I; Sok M; Ihan A; Kosnik M
    Scand J Immunol; 2007 Dec; 66(6):694-702. PubMed ID: 17949407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of PD-1 inhibitor on exhaled nitric oxide and pulmonary function in non-small cell lung cancer patients with and without COPD.
    Suzuki Y; Inui N; Karayama M; Imokawa S; Yamada T; Yokomura K; Asada K; Kusagaya H; Kaida Y; Matsuda H; Koshimizu N; Toyoshima M; Masuda M; Hayakawa H; Hozumi H; Furuhashi K; Enomoto N; Fujisawa T; Nakamura Y; Suda T
    Int J Chron Obstruct Pulmon Dis; 2019; 14():1867-1877. PubMed ID: 31686799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of PD-L1-positive cancer-associated fibroblasts in pN0M0 non-small cell lung cancer.
    Teramoto K; Igarashi T; Kataoka Y; Ishida M; Hanaoka J; Sumimoto H; Daigo Y
    Lung Cancer; 2019 Nov; 137():56-63. PubMed ID: 31546072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune Cell Composition in Human Non-small Cell Lung Cancer.
    Stankovic B; Bjørhovde HAK; Skarshaug R; Aamodt H; Frafjord A; Müller E; Hammarström C; Beraki K; Bækkevold ES; Woldbæk PR; Helland Å; Brustugun OT; Øynebråten I; Corthay A
    Front Immunol; 2018; 9():3101. PubMed ID: 30774636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer.
    Kim CG; Kim G; Kim KH; Park S; Shin S; Yeo D; Shim HS; Yoon HI; Park SY; Ha SJ; Kim HR
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34907028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of the PD-1/PD-L1 immune checkpoint axis during inflammation-associated lung tumorigenesis.
    Narayanapillai SC; Han YH; Song JM; Kebede ME; Upadhyaya P; Kassie F
    Carcinogenesis; 2020 Nov; 41(11):1518-1528. PubMed ID: 32602900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes and risk factor of immune checkpoint inhibitors-related pneumonitis in non-small cell lung cancer patients with chronic obstructive pulmonary disease.
    Zeng Z; Qu J; Yao Y; Xu F; Lu S; Zhang P; Yao Y; Li N; Zhou J; Wang Y
    BMC Pulm Med; 2022 Dec; 22(1):458. PubMed ID: 36456932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered purinergic signaling in the tumor associated immunologic microenvironment in metastasized non-small-cell lung cancer.
    Schmid S; Kübler M; Korcan Ayata C; Lazar Z; Haager B; Hoßfeld M; Meyer A; Cicko S; Elze M; Wiesemann S; Zissel G; Passlick B; Idzko M
    Lung Cancer; 2015 Dec; 90(3):516-21. PubMed ID: 26505137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of mortality from cardiovascular and respiratory causes in patients with chronic obstructive pulmonary disease submitted to follow-up after lung resection for non-small cell lung cancer.
    Volpino P; Cangemi R; Fiori E; Cangemi B; De Cesare A; Corsi N; Di Cello T; Cangemi V
    J Cardiovasc Surg (Torino); 2007 Jun; 48(3):375-83. PubMed ID: 17505444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation-induced cell death drives profound lung CD4(+) T-cell depletion in HIV-associated chronic obstructive pulmonary disease.
    Popescu I; Drummond MB; Gama L; Coon T; Merlo CA; Wise RA; Clements JE; Kirk GD; McDyer JF
    Am J Respir Crit Care Med; 2014 Oct; 190(7):744-55. PubMed ID: 25137293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-17C-mediated innate inflammation decreases the response to PD-1 blockade in a model of Kras-driven lung cancer.
    Ritzmann F; Jungnickel C; Vella G; Kamyschnikow A; Herr C; Li D; Menger MM; Angenendt A; Hoth M; Lis A; Bals R; Beisswenger C
    Sci Rep; 2019 Jul; 9(1):10353. PubMed ID: 31316109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma.
    Kinoshita T; Kudo-Saito C; Muramatsu R; Fujita T; Saito M; Nagumo H; Sakurai T; Noji S; Takahata E; Yaguchi T; Tsukamoto N; Hayashi Y; Kaseda K; Kamiyama I; Ohtsuka T; Tomizawa K; Shimoji M; Mitsudomi T; Asamura H; Kawakami Y
    Eur J Cancer; 2017 Nov; 86():15-27. PubMed ID: 28950145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peripheral PD1-positive CD4 T-Lymphocyte Count Can Predict Progression-free Survival in Patients With Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitor.
    Inomata M; Kado T; Okazawa S; Imanishi S; Taka C; Kambara K; Hirai T; Tanaka H; Tokui K; Hayashi K; Miwa T; Hayashi R; Matsui S; Tobe K
    Anticancer Res; 2019 Dec; 39(12):6887-6893. PubMed ID: 31810958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Impact of Chronic Obstructive Pulmonary Disease on Risk of Recurrence in Patients with Resected Non-small Cell Lung Cancer].
    Qiang G; Yu Q; Liang C; Song Z; Shi B; Guo Y; Liu D
    Zhongguo Fei Ai Za Zhi; 2018 Mar; 21(3):215-220. PubMed ID: 29587946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of PD-L1 expression in combination with CD8
    Yang H; Shi J; Lin D; Li X; Zhao C; Wang Q; Zhang L; Jiang T; Zhao S; Liu X; Jia Y; Zhang Y; Cai W; Zhou C
    Cancer Med; 2018 Jan; 7(1):32-45. PubMed ID: 29168339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.